The Receptor Tyrosine Protein Kinase ERBB 4 pipeline drugs market research report outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Receptor Tyrosine Protein Kinase ERBB 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Cardiovascular, Central Nervous System, and Gastrointestinal which include the indications Non-Small Cell Lung Cancer, Gastric Cancer, Systolic Heart Failure, Diastolic Heart Failure (HFpEF), Neuropathic Pain (Neuralgia), Amyotrophic Lateral Sclerosis, Ulcerative Colitis, and Crohn’s Disease (Regional Enteritis). It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Receptor Tyrosine Protein Kinase ERBB 4 pipeline targets constitutes close to 16 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, and Preclinical stages are 2, 2, 7, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Receptor Tyrosine Protein Kinase ERBB 4 overview
Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.
For a complete picture of Receptor Tyrosine Protein Kinase ERBB 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
